Presentation Joana Graveland-Bikker and Pepijn Burgers

Applying the AdVacPlatform to Development of a COVID-19 Vaccine

Abstract

The AdVac® platform, which comprises an Adenovirus vector being produced by means of our proprietary packaging cell line, was applied for development of a COVID-19 vaccine candidate. Here we will describe several key elements of the AdVac® platform, ranging from the viral vector design, drug substance and drug product manufacturing processes, prior product and stability knowledge up to regulatory dossier templates. All these elements were fundamental for acceleration of the vaccine development and preparation of the market authorization application. The strategy for use of the AdVac® platform to enable rapid manufacturing of a large vaccine supply to combat COVID-19 takes into account the foreseen supply chain challenges, such as large-scale manufacturing at different production sites across the globe and product storage.

Speaker CV + photo

Joanke Graveland-Bikker CV

Joanke is a Senior Technical Integrator at Janssen Vaccines and Prevention B.V. in Leiden, The Netherlands. She is responsible for drug substance development – both early and late stage - of various vaccine candidates, including EMA approval of ZABDENO®. Prior to joining the company 12 years ago she was a post-doc in Biomedical Engineering at MIT, Cambridge MA and in Medicinal Chemistry at Leiden University, The Netherlands. Joanke received her MSc in food science and technology from Wageningen University and her PhD in chemistry from Utrecht University, both in the Netherlands.

Pepijn Burgers CV

Pepijn Burgers is an Associate Scientific Director at Janssen Vaccines and Prevention B.V., located in Leiden, Netherlands. He is head of the product characterization group which is responsible for comparability assessments, product characterization, and criticality analyses focused primarily on viral vectors. He previously worked on Janssen's Ebola vaccine (EMA approval) and more recently was responsible for the product characterization, comparability and control strategies of Janssen's COVID-19 vaccine candidate. Prior to joining Janssen, he worked at Merck contributing to the successful tech transfers and approval of Keytruda. Pepijn received his B.S. in biology/chemistry from University of New Brunswick (Canada) and M.S. and Ph.D. from Utrecht University (Netherlands).